Article Text

Download PDFPDF

DGI-053 Pharmacoeconomic Considerations Regarding the Treatment of Chronic Hepatitis C with Protease Inhibitors
  1. A Schillaci1,
  2. C Iacobello2
  1. 1University of Catania, School of Specialization in Hospital Pharmacy, Catania, Italy
  2. 2Ferrarotto Hospital, Department of infectious diseases, Catania, Italy


Background The standard care for chronic hepatitis C is a double treatment that consists of associating ribavirin (RBV) and peginterferon (pegINF) α-2a/2b. New therapeutic agents telaprevir and boceprevir have recently been approved in Europe in combination with pegINF and RBV for the treatment of patients with genotype 1 HCV who have not been treated previously or when standard treatment has failed. They are serine protease inhibitors and belong to a new class of drugs: direct acting antivirals (DDAs).

Purpose To evaluate the pharmacoeconomic aspects of triple therapy with RBV, pegIFN and telaprevir or boceprevir, as reported in the literature.

Materials and Methods Cut-off guidelines have been established to quantify the suitability of new treatments based on the cost of treatment per quality-adjusted life year (QALY). The impact of using the new drugs was assessed on a hypothetical group of 14,000 patients infected with HCV (genotype 1). Unfortunately the price of the new drugs has not yet been negotiated in Italy; this represents a limit on the evaluation. The results are expressed in terms of Incremental cost-effectiveness ratios (ICERs).

Results The cost was estimated at €31,000/patient, 236.5 M€ over a period of 30 years. The ICER calculated to 20 years was €29.485/QALY while at 30 years was €18.291/QALY. Investment in these new molecules is favourable from a time horizon of 20 years.

Conclusions Boceprevir and telaprevir with standard treatment are cost effective considering the lifetime incidence of liver complications, quality-adjusted life years and the incremental cost-effectiveness ratio. The cost effectiveness depends on the adherence to the treatment; it could be improved if the diagnostic and therapeutic pathways were optimised.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.